- Home
- CIFR vs IONS Comparison
CIFR vs IONS Comparison
Compare CIFR & IONS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CIFR
- IONS
- Stock Information
- Founded
- CIFR 2021
- IONS 1989
- Country
- CIFR United States
- IONS United States
- Employees
- CIFR N/A
- IONS N/A
- Industry
- CIFR Investment Bankers/Brokers/Service
- IONS Biotechnology: Pharmaceutical Preparations
- Sector
- CIFR Finance
- IONS Health Care
- Exchange
- CIFR Nasdaq
- IONS Nasdaq
- Market Cap
- CIFR 6.7B
- IONS 6.8B
- IPO Year
- CIFR N/A
- IONS 1991
- Fundamental
- Price
- CIFR $25.37
- IONS $74.46
- Analyst Decision
- CIFR Strong Buy
- IONS Strong Buy
- Analyst Count
- CIFR 11
- IONS 21
- Target Price
- CIFR $22.85
- IONS $80.24
- AVG Volume (30 Days)
- CIFR 54.6M
- IONS 2.0M
- Earning Date
- CIFR 11-03-2025
- IONS 10-29-2025
- Dividend Yield
- CIFR N/A
- IONS N/A
- EPS Growth
- CIFR N/A
- IONS N/A
- EPS
- CIFR N/A
- IONS N/A
- Revenue
- CIFR $206,454,000.00
- IONS $966,957,000.00
- Revenue This Year
- CIFR $77.60
- IONS $27.96
- Revenue Next Year
- CIFR $73.72
- IONS $2.33
- P/E Ratio
- CIFR N/A
- IONS N/A
- Revenue Growth
- CIFR 35.41
- IONS 20.41
- 52 Week Low
- CIFR $1.86
- IONS $23.95
- 52 Week High
- CIFR $25.11
- IONS $75.49
- Technical
- Relative Strength Index (RSI)
- CIFR 70.68
- IONS 66.73
- Support Level
- CIFR $20.10
- IONS $71.96
- Resistance Level
- CIFR $25.11
- IONS $75.49
- Average True Range (ATR)
- CIFR 2.42
- IONS 2.13
- MACD
- CIFR 0.22
- IONS -0.36
- Stochastic Oscillator
- CIFR 93.77
- IONS 82.16
About CIFR Cipher Mining Inc.
Cipher Mining Inc ia an emerging technology company that operates in the Bitcoin mining ecosystem in the United States. The company is developing a cryptocurrency mining business, specializing in Bitcoin. The company is expanding and strengthening the Bitcoin network's critical infrastructure in the United States.
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.